1. Home
  2. GNLX vs APLT Comparison

GNLX vs APLT Comparison

Compare GNLX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLX
  • APLT
  • Stock Information
  • Founded
  • GNLX 2001
  • APLT 2016
  • Country
  • GNLX United States
  • APLT United States
  • Employees
  • GNLX N/A
  • APLT N/A
  • Industry
  • GNLX Biotechnology: Pharmaceutical Preparations
  • APLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLX Health Care
  • APLT Health Care
  • Exchange
  • GNLX Nasdaq
  • APLT Nasdaq
  • Market Cap
  • GNLX 85.0M
  • APLT 80.3M
  • IPO Year
  • GNLX 2023
  • APLT 2019
  • Fundamental
  • Price
  • GNLX $5.34
  • APLT $0.65
  • Analyst Decision
  • GNLX Strong Buy
  • APLT Buy
  • Analyst Count
  • GNLX 4
  • APLT 7
  • Target Price
  • GNLX $18.25
  • APLT $6.10
  • AVG Volume (30 Days)
  • GNLX 396.9K
  • APLT 3.5M
  • Earning Date
  • GNLX 03-31-2025
  • APLT 03-05-2025
  • Dividend Yield
  • GNLX N/A
  • APLT N/A
  • EPS Growth
  • GNLX N/A
  • APLT N/A
  • EPS
  • GNLX N/A
  • APLT N/A
  • Revenue
  • GNLX $8,000.00
  • APLT N/A
  • Revenue This Year
  • GNLX N/A
  • APLT N/A
  • Revenue Next Year
  • GNLX N/A
  • APLT $2,622.90
  • P/E Ratio
  • GNLX N/A
  • APLT N/A
  • Revenue Growth
  • GNLX N/A
  • APLT N/A
  • 52 Week Low
  • GNLX $1.60
  • APLT $0.54
  • 52 Week High
  • GNLX $8.67
  • APLT $10.62
  • Technical
  • Relative Strength Index (RSI)
  • GNLX 72.84
  • APLT 35.67
  • Support Level
  • GNLX $4.10
  • APLT $0.54
  • Resistance Level
  • GNLX $5.89
  • APLT $0.66
  • Average True Range (ATR)
  • GNLX 0.54
  • APLT 0.06
  • MACD
  • GNLX 0.14
  • APLT 0.09
  • Stochastic Oscillator
  • GNLX 79.70
  • APLT 81.26

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: